Head Of Australia’s Bone Medical Ousted After Two Years
This article was originally published in PharmAsia News
Australia's Bone Medical biopharmaceutical company is losing its managing director of the past two years. Troels Jordansen lost his job in a restructuring of the company's board of directors, to be replaced soon by an unnamed person from the United States. Bone Medical, which concentrates on breakthrough treatments for bone and joint degeneration and related diseases, reported having less than $124,000 in cash at the end of the March quarter. (Click here for more
You may also be interested in...
BD Diagnostics has gained emergency use authorization (EUA) for a handheld rapid COVID-19 antigen test that could play a pivotal role in fighting an ongoing surge of coronavirus outbreaks. See what US FDA commissioner Stephen Hahn said about it here.
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.
FDA approval for Perrigo's ANDA for two loperamide products listed as tablets follows CBE label changes Johnson & Johnson and BionPharma made for their branded OTCs containing the ingredient in 2019.